

Ref: FOIA Reference 2019/20-098

Royal Stoke University Hospital
Quality, Safety and Compliance Department
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 5th June 2019

Email foi@uhnm.nhs.uk

Dear

I am writing in response to your email dated 21st May 2019 requesting information under the Freedom of Information Act (2000) regarding non-small cell lung cancer (NSCLC).

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 I have a FOI request with regards to Cancer treatment within your organisation
1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for non-small cell lung cancer (NSCLC) with the following:**

- **Paclitaxel**
- **Gemcitabine**
- **Osimertinib**
- **Carboplatin and Pemetrexed**
- **Cisplatin and Pemetrexed**
- **Pembrolizumab monotherapy**
- **Pembrolizumab in combination**
- **Atezolizumab**
- **Nivolumab**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

Paclitaxel	0
Gemcitabine	11
Osimertinib	Less than 5
Carboplatin and Pemetrexed	21
Cisplatin and Pemetrexed	14
Pembrolizumab monotherapy	38
Pembrolizumab in combination	18
Atezolizumab	18
Nivolumab	Less than 5

Other active systemic anti-cancer therapy:	See below
Carboplatin & Gemcitabine	Less than 5
Cisplatin & Gemcitabine	Less than 5
Carboplatin, Etoposide & RT	Less than 5
Carboplatin & Vinorelbine PO	28

Q2 Does your Health Trust participate in any ongoing clinical trials for the treatment of metastatic non-small cell lung cancer patients?

A2 ADSCAN is currently being setup.

Q3 If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

A3 Not applicable

Q4 Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:

- Cetuximab not in combination with FOLFIRIE or FOLOX
- Cetuximab in combination with FOLFIRI
- Cetuximab in combination with FOLFOX
- Panitumumab not in combination with FOLFIRI or FOLFOX
- Panitumumab in combination with FOLFIRI
- Panitumumab in combination with FOLFOX
- Nivolumab
- Aflibercept
- Bevacizumab
- Ramucirumab
- Regorafenib
- Sorafenib
- Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

Cetuximab not in combination with FOLFIRIE or FOLOX	0
Cetuximab in combination with FOLFIRI	29
Cetuximab in combination with FOLFOX	8
Panitumumab not in combination with FOLFIRI or FOLFOX	0
Panitumumab in combination with FOLFIRI	Less than 5

Panitumumab in combination with FOLFOX	Less than 5
Nivolumab	0
Aflibercept	0
Bevacizumab	0
Ramucirumab	0
Regorafenib	0
Sorafenib	0
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU) :	See below
5FU Weekly	Less than 5
CAPIRI	13
CAPOX	81
FOLFIRI	47
FOLFOX	40
IRINOTECAN	Less than 5
TEGAFUR	0
LONSURF	5

Q5 Does your Health Trust participate in any ongoing clinical trials for the treatment of colorectal cancer patients?

A5 Yes

Q6 If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

A6 None.
Trigger.

- Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good and Poor Responders to Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial to avoid surgery with 'watch and wait' or intensify treatment according to mrTRG.

Q7 Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma)?

A7 Fifty two (52) patients were diagnosed with a primary Head and Neck cancer (Squamous Cell Carcinoma) at UHNM over the period October 2018 to March 2019

Q8 If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients?

- Locally advanced
- Recurrent metastatic
- Unable to split

A8 Unable to split

Q9 Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)

- Carboplatin (only or in combination with 5-FU)
- Cisplatin (only or in combination with 5-FU)
- Cetuximab with / without chemotherapy
- Cetuximab with radiotherapy
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Nivolumab
- Docetaxel (only or in combination with 5-FU)
- Fluorouracil (5-FU)
- Radiotherapy only
- Other

A9 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

Carboplatin (only or in combination with 5-FU)	11
Cisplatin (only or in combination with 5-FU)	19
Cetuximab with / without chemotherapy	0
Cetuximab with radiotherapy	Less than 5
Pembrolizumab monotherapy	0
Pembrolizumab with chemotherapy	0
Nivolumab	0
Docetaxel (only or in combination with 5-FU)	20
Fluorouracil (5-FU)	0
Radiotherapy only	
Other - 0	0

Q10 Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients?

A10 Yes

Q11 If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

A11 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

- ION less than 5 patients
- ART-DECO less than 5 patients

Q12 Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:

- **Cisplatin single agent**
- **Cisplatin in combination with another agent**
- **Carboplatin single agent**
- **Carboplatin in combination with another agent**
- **Nivolumab**
- **Pembrolizumab**
- **Atezolizumab**
- **Other active systemic anti-cancer therapy**

A12 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

Cisplatin single agent	0
Cisplatin in combination with another agent	15
Carboplatin single agent	0
Carboplatin in combination with another agent	9
Nivolumab	0
Pembrolizumab	10
Atezolizumab	Less than 5
Other active systemic anti cancer therapy	

Q13 Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients?

A13 No

Q14 If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

A14 Not applicable

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,



Jean Lehnert
Information Governance Manager